71 related articles for article (PubMed ID: 20715163)
1. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells.
Abbasi M; Lavasanifar A; Berthiaume LG; Weinfeld M; Uludağ H
Cancer; 2010 Dec; 116(23):5544-54. PubMed ID: 20715163
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
3. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters).
Yin Q; Shen J; Chen L; Zhang Z; Gu W; Li Y
Biomaterials; 2012 Sep; 33(27):6495-506. PubMed ID: 22704597
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles.
Gao Y; Chen L; Zhang Z; Chen Y; Li Y
Biomaterials; 2011 Feb; 32(6):1738-47. PubMed ID: 21112086
[TBL] [Abstract][Full Text] [Related]
5. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Abbasi M; Lavasanifar A; Uludag H
Med Res Rev; 2013 Jan; 33(1):33-53. PubMed ID: 21523793
[TBL] [Abstract][Full Text] [Related]
6. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA.
Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z
Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680
[TBL] [Abstract][Full Text] [Related]
7. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
[TBL] [Abstract][Full Text] [Related]
8. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Yu L; Wu WK; Li ZJ; Liu QC; Li HT; Wu YC; Cho CH
Mol Pharmacol; 2009 Jun; 75(6):1364-73. PubMed ID: 19264847
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
14. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
Yadav S; van Vlerken LE; Little SR; Amiji MM
Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
16. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
17. Virus-mimetic polymeric micelles for targeted siRNA delivery.
Xiong XB; Uludağ H; Lavasanifar A
Biomaterials; 2010 Aug; 31(22):5886-93. PubMed ID: 20427082
[TBL] [Abstract][Full Text] [Related]
18. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]